Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by Mohammed Hussen Bule
Total Records ( 2 ) for Mohammed Hussen Bule
  Mohammed Hussen Bule , Faheem Maqbool , Ishtiaq Ahmed , Kuldeep Dhama and Hafiz Muhammad Nasir Iqbal
  From decades’ tuberculosis (TB) affecting individual and a huge number of people die every year. It causes ill-health among millions of individuals each year and ranks as the second leading cause of death from an infectious disease worldwide. The number of TB deaths has been unacceptably increased to a large extent and most cases are preventable if people get in time access to health care for a diagnosis and the right treatment. Multi-drug resistance is the fact that in TB patients are growing rapidly and difficult to treat. Treatment of MDR-TB is more complicated and longer than treatment of TB with no resistance. With advancements in the therapy of TB, now ideal treatments have been developed and many combination therapies are well recommended for MDR. The development of MDR-TB can be caused by a treatment that is inadequate, given the drug susceptibility pattern of the MTB strain. Few cohort studies provided information on treatment regimens and drug resistance profiles before treatment and at failure or recurrence or genotyping information at failure or recurrence. To monitor the development of acquired drug resistance, we suggest that given sufficient resources are available, TB treatment cohort studies or surveillance systems measure both the drug resistance profile and genotype information before starting treatment and at failure or recurrence. The emergence of MDR-TB and XDR-TB, the need for new TB drug regimens and rapid DST is intuiting globally. In future, more research with a focus on MDR and TB is required to avoid and counteract its associated complications.
  Mohammed Hussen Bule , Ishtiaq Ahmed , Faheem Maqbool and Muhammad Anjum Zia
  Malaria causes over a million deaths each year (2 percent of the global total of deaths), with hundreds of millions of clinical episodes per annum. The greatest challenge to malaria control and eradication is the emergence of malaria parasites that are resistant to antimalarial drugs. The development of resistance to conventionally used anti-malarial drugs, such as chloroquine (CQ) and Sulfadoxine-Pyrimethamine (SP) has been documented. To counter this WHO recommended that artemisinin-based combination therapy (ACT) should be used for treating uncomplicated Plasmodium falciparum malaria to ensure efficacy and reduce the emergence of drug-resistant parasites. Currently available antimalarial drugs are ineffective and their number is declining because of the widespread resistance. Thus, the new antimalarial agent is in urgent demand; however, the development of new antimalarial drug presents challenges due to resistance, toxicity, minimal efficacy of those on the pipeline and high cost of drug research. Identification of novel drug targets and design of new chemical compounds acting on new targets is important to control the emergence of resistance to existing drugs. In this regard, a natural product derived synthetic analogs of febrifugine containing quinazolinone scaffold can be considered best. Therefore, quinazolinones are potential compounds in seeking for novel drugs that act against the malarial pathogen. Hence, in this review compounds containing quinazolinone structure and possessing antimalarial activities are covered.
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility